Time is Brain, a spin‑off from Germans Trias Hospital (Barcelona), providing advanced stroke care to +1.8M people, and a pioneer in clinical trials shaping global stroke guidelines.
This overview is generated using artificial intelligence based on information available
on the platform’s project page and publicly accessible data. It is provided for
informational purposes only and does not constitute investment advice, financial
guidance, risk assessment, or project scoring. Platforms and project owners are not
involved in the creation, review, or endorsement of this content.
AI project overview
Condensed summary based on project data
<h1><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">Time is Brain, S.L. — Crowdfunding Investor Memo</span></span></h1>
<p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><em>A portable, real-time device that reads a brain-signal biomarker (N20) to help decide which stroke patients should receive clot-removal surgery.</em></span></span></p>
<p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">Sector: <strong>Medtech (Class IIb device / NACE 7210)</strong> · Stage: <strong>Seed / pre-CE-mark, pre-revenue</strong> · HQ: <strong>Badalona / Barcelona, Spain</strong> · Raise: <strong>€2.5M target (€430k via Capital Cell)</strong></span></span></p>
<table cellspacing="0" class="Table" style="border-collapse:collapse; width:6.5in">
<tbody>
<tr>
<td style="background-color:#faeeda; vertical-align:top; width:208px">
<p style="text-align:center"><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">AI SCORE</span></strong></span></span></p>
</td>
<td style="vertical-align:top; width:416px">
<p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong>Why this score:</strong></span></span></p>
</td>
</tr>
<tr>
<td style="background-color:#faeeda; height:.75in; vertical-align:top; width:208px">
<p style="text-align:center"> </p>
</td>
<td style="height:.75in; vertical-align:top; width:416px">
<ul>
<li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">Peer-reviewed pivotal evidence (PROMISE, n=223): the N20 signal predicted good recovery with sensitivity 93% and an adjusted odds ratio of 9.9 — unusually strong clinical grounding for a seed-stage device.</span></span></li>
</ul>
</td>
</tr>
<tr>
<td style="background-color:#faeeda; vertical-align:top; width:208px">
<p style="text-align:center"><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="font-size:26.0pt"><span style="color:black">63 / 100</span></span></strong></span></span></p>
</td>
<td style="vertical-align:top; width:416px">
<ul>
<li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">Founders are genuine stroke key opinion leaders (CSO Antoni Dávalos, co-PI of the landmark REVASCAT trial, H-index 77), independently verifiable.</span></span></li>
</ul>
</td>
</tr>
<tr>
<td style="background-color:#faeeda; vertical-align:top; width:208px">
<p style="text-align:center"><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">⭐ Moderate</span></strong></span></span></p>
</td>
<td style="vertical-align:top; width:416px">
<ul>
<li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">Still pre-CE-mark: the CE target has already slipped from Q4-2024/Q1-2025 to “during 2026,” and 50% of the round is gated on milestones (CE Mark, first sales) that have slipped once.</span></span></li>
</ul>
</td>
</tr>
<tr>
<td style="background-color:#faeeda; vertical-align:top; width:208px">
<p style="text-align:center"> </p>
</td>
<td style="vertical-align:top; width:416px">
<ul>
<li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">Pre-revenue with the cap table and financial statements link-only (not in the materials), and deal terms (liquidation preference, anti-dilution type, drag threshold) marked “Yes” but undetailed.</span></span></li>
</ul>
</td>
</tr>
<tr>
<td style="background-color:#faeeda; vertical-align:top; width:208px">
<p style="text-align:center"> </p>
</td>
<td style="vertical-align:top; width:416px">
<ul>
<li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">One unreconciled funding figure: €3.3M EIC grant in the company annex vs €2.5M in all public sources and the peer-reviewed paper.</span></span></li>
</ul>
</td>
</tr>
</tbody>
</table>
<p> </p>
<table cellspacing="0" class="Table" style="border-collapse:collapse; border:none; width:6.5in">
<tbody>
<tr>
<td style="background-color:#e6f1fb; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:1px solid #cccccc; vertical-align:top; width:624px">
<p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><span style="color:black">ℹ️ <strong>This is not investment advice.</strong> </span></span></span><span style="font-size:10pt"><span style="font-family:'Times New Roman',serif"><span style="color:#000000">The purpose of this overview is to help potential investors preselect crowdfunding projects quickly without making a final investment decision. Before investing, the final selected project should be reviewed in detail based on the information provided by the company on the respective crowdfunding platform. AI can make mistakes, so you need to double-check data. </span></span></span></p>
</td>
</tr>
</tbody>
</table>
<h1><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">🏢 Company description</span></span></h1>
<p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">Time is Brain, S.L. (TiB) is a Spanish medtech spin-off from Hospital Germans Trias i Pujol, founded in July 2020 by neurologists Alicia Martínez Piñeiro (CEO), Antoni D&aacu
…
Equity crowdfunding
